[]

FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	C/O FENNEC PHARMACEUTICALS, INC. PO BOX 13628, 68 TW ALEXANDER DRIVE street) RESEARCH TRIANGLE NC 27709			FENNEC PHARMACEUTICALS INC. [5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)	(First)	. ,	11/02	e of Earliest Transa	ction (Month/E	Day/Year)	X X	Director Officer (give title below) CHIEF EXECU	below	(specify)			
PO BOX 13628, (Street) RESEARCH TRIANGLE			/E 4. If An	nendment, Date of	Original Filed	(Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Form filed by One Form filed by Mor Person	e Reporting Pers	son			
PARK (City)	(State)	(Zip)		neck this box to indica tisfy the affirmative de	te that a transa efense conditior	on Indication ction was made pursuant to a is of Rule 10b5-1(c). See Ins	truction 1	0.	plan that is intend	led to			
		Table I - Noi	n-Derivative S	ecurities Acq	uired, Disp	osed of, or Benefi	cially	Owned					
1. Title of Security	(Instr. 3)		2. Transaction Date	2A. Deemed Execution Date.	3. Transaction	4. Securities Acquired (A) Disposed Of (D) (Instr. 3.		5. Amount of Securities	6. Ownership Form: Direct	7. Nature of Indirect			

	(Month/Day/Year) if any (Month/		Code (Instr. 8)		5)			Beneficially Owned Following Reported	(D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common shares ⁽¹⁾	11/03/2023		М		74,793	A	\$1.59	307,631	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0.9.,	paro,	ouno	,	manico	, optiono,	001110111		and obj				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) (Disp of (I	umber vative urities uired or oosed D) (Instr. and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		te Amount of		ount of Derivative security erlying (Instr. 5) vative urity (Instr. 3		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option Contract ⁽²⁾	\$1.59	11/03/2023		М			74,793	01/24/2014	01/24/2024	Options	74,793	\$1.59	1,596,040	D	

Explanation of Responses:

1. Shares acquired through the exercise of an option contract with a strike price of \$1.59 and an expiration date of January 24, 2024.

2. Represents options granted on January 24, 2014, with a strike price of \$1.59 and an expiration date of January 24, 2024.

/s/ Rostislav Roykov

** Signature of Reporting Person

<u>11/03/2023</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.